背景
目前,癌症已成为危害人类健康最严重的疾病之一,死亡率仅次于心血管系统疾病。除遗传因素变化外,肿瘤细胞所处的外周环境改变被认为是肿瘤发生发展及抗药性产生的主要原因。肿瘤微环境(Tumor microenvironment,TME)是指肿瘤细胞生成发展过程中所处的局部环境,包括肿瘤周围的血管、免疫细胞、成纤维细胞、骨髓源性炎性细胞、各种信号分子和细胞外基质(extracellular matrix,ECM)等。TME中的细胞和非细胞成分可以通过调控不同的级联信号通路传导过程,对肿瘤的发生,生长,侵袭,转移以及对治疗的反应进行重新编程。
现全球越来越多医药研发企业着眼TME进行抗体药物开发,ACROBiosystems开发了TGF-β、Notch,Integrin等重要信号通路靶点,助力癌症治疗药物开发,帮助您缩短研发周期。
验证数据
高纯度——MALS验证
-
- The purity of Human DLL3, His Tag(Cat. No. DL3-H52H4) is more than 95% and the molecular weight of this protein is around 55-65 kDa verified by SEC-MALS.
生物活性验证(Bioactivity)
> ELISA
-
- Immobilized ActiveMax® Human TGFB1, Tag Free (Cat. No. TG1-H4212) at 0.2 μg/mL (100 μL/well) can bind Human TGFBR2, Fc Tag (Cat. No. TG2-H5252) with a linear range of 0.08-1 ng/mL (QC tested).
-
> BLI
-
- Loaded Human NOTCH2, Fc Tag (Cat. No. NO2-H5255) on Protein A Biosensor, can bind Human DLL4, His Tag (Cat. No. DL4-H5227) with an affinity constant of 77.6 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
-
> SPR
-
- Human HGF R Protein, Fc Tag (Cat. No. MET-H5256) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human HGF Protein, His Tag (Cat. No. HGF-H52H3) with an affinity constant of 75.2 pM as determined in a SPR assay (Biacore 8K) (QC tested).
-